Quick answer
The target dose reached after titration, taken long-term for ongoing therapeutic effect. For Wegovy this is typically 2.4 mg weekly; for Zepbound, 5, 10, or 15 mg weekly.
Full definition
The maintenance dose is the steady, ongoing dose a patient continues after titration is complete. For Wegovy, maintenance is 2.4 mg subcutaneously once weekly (with 1.7 mg as a fallback for tolerability). For Zepbound, maintenance is individualized at 5, 10, or 15 mg once weekly. For Ozempic in T2D, maintenance is 0.5, 1, or 2 mg weekly. Some patients respond well at lower maintenance doses; others require the maximum. Reaching maintenance does not mean weight loss is complete — the plateau effect typically arrives 12-18 months in.
Deep dive
Maintenance Dose: complete reference
The maintenance dose is the steady-state dose of a medication at which the patient remains long-term after completing titration. For GLP-1 medications, the standard maintenance doses are: Wegovy 2.4mg weekly (with new high-dose option of 7.2mg), Zepbound 15mg weekly (with lower 10mg or 5mg as personalized maintenance), Ozempic 1mg-2mg weekly, Mounjaro 15mg weekly, Saxenda 3mg daily. Maintenance dose decisions balance maximum efficacy (typically achieved at the highest dose) against tolerability + cost. Many patients use "personalized maintenance" — staying at a lower dose (e.g., 1.7mg semaglutide instead of 2.4mg) once goal weight is achieved, accepting slightly less aggressive weight loss for better long-term tolerability. After discontinuation, the maintenance dose strategy resets — restarting requires gradual titration from 0.25mg or lower starter dose. The maintenance dose is NOT a dose that "weans off" the drug — GLP-1 medications produce regain when stopped regardless of dose at discontinuation.
- In practice
- After 16 weeks of titration, you reach Wegovy 2.4mg maintenance. Some patients stay there forever; others reduce to 1.7mg once goal weight is stable, accepting slower additional loss for better tolerability.
- Clinical context
- Personalized maintenance dosing is increasingly common — particularly при transitioning from weight loss to weight maintenance phase.
Medications
Maintenance Dose is most directly relevant to the following GLP-1 medications:
Related terms
- Titration — The gradual dose escalation schedule used when starting GLP-1 therapy. Typically increases every 4 w…
- Weight-Loss Plateau — The point at which weight loss slows or stops despite continued GLP-1 therapy. Most patients plateau…
- Subcutaneous Injection — An injection delivered into the fat layer just below the skin (typically abdomen, thigh, or upper ar…
Continue learning
GLP1Zoom glossary is educational reference. Definitions are summary interpretations of clinical sources and not a substitute for prescribing-information detail. Full disclaimer.
References
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms и Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly для Treatment of Obesity (Jastreboff et al., NEJM)(2022)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide в Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes в T2D (Marso et al., NEJM)(2016)